I recall one of my college classes from years ago, when the professor covered a subject that was rather difficult to understand. At the end, she paused, looked around the room, and asked if we all understood. We must have had blank expressions on our faces or our heads tilted…
Therapy and counseling
As all good things must come to an end, so did our epic overseas adventure in a recreational vehicle that was too tiny to live in and too big to drive into any European village. We devoted those five weeks to quality time with family, unplugging from devices, and…
Two weeks ago, I was notified that one of the lesions on my brain has grown. This led me and my care team to decide it was time to switch multiple sclerosis (MS) treatments. Soon after I was diagnosed with relapsing-remitting multiple sclerosis in 2017,…
The U.S. Food and Drug Administration (FDA) has given the green light to Immpact Bio to conduct a Phase 1 clinical trial to test IMPT-514, its experimental cell therapy, in people with multiple sclerosis (MS). With the investigational new drug (IND) clearance by the FDA, Immpact Bio now…
Abata Therapeutics has received an investment from Bristol Myers Squibb to support the development of its experimental regulatory T-cell (Treg) therapies for severe autoimmune and inflammatory diseases, including progressive multiple sclerosis (MS). The new equity investment from the global biopharmaceutical company follows last week’s green light from…
Note: This column refers to the author’s own experience with Gilenya (fingolimod). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. On a recent Friday, all was calm and peaceful in my household. I was bundled up in my bed watching…
TG Therapeutics plans to soon launch a Phase 1 clinical trial to investigate the CAR T-cell therapy azercabtagene zapreleucel, or azer-cel, in people with progressive forms of multiple sclerosis (MS). The announcement comes after the U.S. Food and Drug Administration (FDA) cleared TG’s…
Indapta Therapeutics will launch a Phase 1 clinical trial in the U.S. in the second half of 2024 to explore its cell-based therapy IDP-023 in people with progressive forms of multiple sclerosis (MS). The announcement follows the U.S. Food and Drug Administration’s (FDA) clearance of the company’s investigational…
A few years before I was married and had even thought about having children, I was at home alone when there was a knock at the door. I hadn’t lived there for long, and a small group of people had dropped by to welcome me to the neighborhood. I invited…
Iaso Biotherapeutics has received the green light from the U.S. Food and Drug Administration (FDA) to start clinical trials of its investigational CAR T-cell therapy equecabtagene autoleucel (eque-cel) in people with multiple sclerosis (MS). The FDA’s clearance of the company’s investigational new drug (IND) application makes MS the…
Immutep has been cleared to start a Phase 1 clinical trial in the Netherlands to test IMP761, its experimental antibody therapy for autoimmune diseases such as multiple sclerosis (MS), in healthy volunteers. The first-in-human Phase 1 clinical trial seeks to assess the safety and pharmacological properties of IMP761.
I’ve been betrayed by my breakfast cereal. Other than eating it, I’m not sure what I did to deserve this. I always liked cereal and thought we had a good relationship. The only disagreement we’ve had was when I tried mixing two high-fiber cereals. The result was a bowl of…
People with multiple sclerosis (MS) who have cognitive impairment tend to report worse mental and physical quality of life than patients who don’t have cognitive issues, a study reports. Adults with MS who have cognitive problems are also less likely to be employed. The study, “Association…
If I haven’t warned you that bits of my past in the military would sometimes leak into my present as a Multiple Sclerosis News Today columnist, consider yourself warned. I was in the U.S. Army for almost 22 years, so it’s bound to happen occasionally. If I’d become an…
Rehabilitation approaches involving virtual reality (VR) may have beneficial effects on cognitive function and anxiety in people with multiple sclerosis (MS), but more research is needed to better understand its effects, according to a recent meta-analysis of 10 clinical trials. Small gains in certain aspects of cognition, including immediate…
Charles River Laboratories has joined up with FibroBiologics to manufacture the company’s spheroids for clinical trials in multiple sclerosis (MS) and several other conditions. The spheroids are groups of fibroblast cells arranged in a three-dimensional (3D) structure that more closely resemble how cells organize in living tissues.
NKTR-0165, an antibody that targets the tumor necrosis factor receptor type 2 (TNFR2), will continue to be developed by Nektar Therapeutics as a candidate for treating multiple sclerosis (MS) and other autoimmune diseases. The experimental therapy was developed under a 2021 collaboration between Nektar and Biolojic…
In case there was any confusion, “Chairborne” is not an advice column. Well, not the kind of advice that comes from raw wisdom, anyway. Most of my lessons are closer to cautionary tales than anything else. The only reason I can suggest avoiding any mistake is because I’ve already…
Kelly Earley teaches family and consumer sciences at a middle school. (Photos courtesy of Kelly Earley) Day 28 of 31 This is Kelly Earley’s story: I have been living with multiple sclerosis (MS) since I was 17 years old but was only officially diagnosed when I was 24…
The Polish biotechnology company PolTREG plans to launch Phase 2 trials testing its Tregs therapy — the T-cell-based treatment PTG-007 — in people with multiple sclerosis (MS) in Poland later this year. The biotech company has earned a Current Good Manufacturing Practice (CGMP) certification for its new manufacturing…
Researchers at Stanford University have partnered with Kyverna Therapeutics to conduct an investigator-initiated clinical trial of the company’s cell-based therapy, KYV-101, in people with progressive forms of multiple sclerosis (MS) without relapses. The open-label Phase 1 trial (NCT06138132) will take place at the Stanford Multiple Sclerosis…
COMPASS, a digital tool that provides support for managing the daily challenges of living with a long-term health condition such as multiple sclerosis (MS), significantly reduces psychological distress and improves mental health in these patients, data from a randomized clinical trial show. The intervention consists of multiple online modules…
A non-invasive scan that measures network activity across the brain was able to predict the outcomes of behavioral therapies designed to improve cognitive function in people with multiple sclerosis (MS), a study demonstrates. Brain network function, as assessed by the test, called magnetoencephalography (MEG), “could play an important role…
Tyruko (natalizumab), the first biosimilar of Tysabri, is now available in Germany for adults with highly active relapsing-remitting multiple sclerosis (RRMS). As a biosimilar, Tyruko has the same safety and efficacy profile, mechanism of action, and pharmacological properties as Tysabri. Biosimilars are typically sold at lower prices than their reference medication,…
Kyverna Therapeutics has developed a method that enables KYV-101, an experimental CAR T-cell therapy for multiple sclerosis (MS) and other conditions, to be produced in a much shorter timeframe than conventional manufacturing processes, a study shows. The approach took less than three…
Engaging in online sessions of compassion-focused therapy, which works toward getting people to become more compassionate about themselves, may help women with multiple sclerosis (MS) deal with suicidal thoughts, a small study suggests. Compassion-focused therapy also may help these women overcome pain catastrophizing, which is a tendency to view…
I’m not a psychologist, but if you’re a regular reader of my column, you know that I’m intrigued by the subject. I seem to be particularly drawn to unusual conditions and making amateurish comparisons to multiple sclerosis (MS). In my defense, MS has odd symptoms, so…
Adults with multiple sclerosis (MS) or traumatic brain injury report more cognitive fatigue, or exhaustion resulting from mental work, than do healthy individuals — regardless of the nature of the tasks being performed — a study found. However, cognitive fatigue built up at a similar rate among study participants…
When my general practitioner first spoke about the possibility of a diagnosis of multiple sclerosis (MS) in February 2022, I walked out of his office. I broke down in tears; I was terrified. At that instant, my first thought was, “OK, so how long do I have left?”…
A 20-week talk therapy program led to significant reductions in fatigue for people with multiple sclerosis (MS) — benefits that were sustained to the end of the year-long trial regardless of whether patients participated in additional booster sessions. Such sessions were offered two and four months after the end…